Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-182 antagomir
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal, Intratumoral
01
Overview
miR-182 antagomir is a research-stage, chemically modified antisense oligonucleotide (antagomir) designed to inhibit the activity of the endogenous microRNA miR-182. As a member of the miR-183-96-182 cluster, miR-182 is a small non-coding RNA that regulates post-transcriptional gene expression by binding to the 3' untranslated regions of target mRNAs. The antagomir works by competitively binding to miR-182, thereby preventing it from silencing its natural targets, such as Foxo1 and TLR4. This compound has been extensively studied in preclinical models for various conditions: in systemic lupus erythematosus (SLE), it reduces inflammatory cytokines like IFN-γ and IL-6; in oncology, it has been shown to reprogram tumor-associated macrophages in breast cancer and modulate chemotherapy sensitivity in glioblastoma; and in neurology, it is investigated for neuroprotective effects following ischemic stroke.
- Other names
- antagomir-182antagomir182antagomir 182anti-miR-182anti-miR182anti-miR 182miR-182 inhibitormiR182 inhibitormiR 182 inhibitorantagomir-182-5pantagomir182-5pantagomir 182-5p
Beyond the preview
Go deeper on miR-182 antagomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-182 antagomir.